Anthem, BioMarin, CRISPR, GE and More Thursday Afternoon Analyst Calls
24/7 Wall St. looks at some big analyst calls that we have seen so far on Thursday, including Anthem, BioMarin, CRISPR, GE and more.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
With the trading day about halfway over, the broad markets had managed to push higher on the day, despite dipping into the red earlier. This week has been full of ups and downs for each of the major averages, so it is up in the air where the markets will go from here.
24/7 Wall St. is looking at some big analyst calls that we have seen so far on Thursday. We have included the most recent analyst call on each stock, as well as a recent trading history and the consensus targets among analysts.
For those that might have missed it, 24/7 Wall St. had an earlier round of analyst calls on Thursday that included Bumble, Marathon Oil, Qualcomm, Snowflake, Stitch Fix, Walmart and more.
Anthem Inc. (NYSE: ANTM) was upgraded to Buy from Hold and its price target was raised to $375 from $360 at Truist Securities. Shares traded near $321 on Thursday. The 52-week trading range is $171.03 to $340.98. The consensus price target is $368.82.
[nativounit]
American Outdoor Brands Inc. (NASDAQ: AOUT) was initiated by B. Riley at Buy with a $32 price target. The stock was last seen near $21 a share. The 52-week trading range is $12.24 to $30.01, and the consensus price target is $27.25.
American Water Works Co. Inc. (NYSE: AWK | AWK Price Prediction) was upgraded at Janney from Neutral to Buy with a $159 price target. Shares were trading below $137. The stock has changed hands within a 52-week range of $92.00 to $172.56, and it has a consensus price target of $163.60.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was resumed at Guggenheim with a Buy rating. The shares traded near $77. The 52-week range is $68.25 to $131.95, and analysts have a consensus price target of $107.79.
Charles Schwab Corp. (NYSE: SCHW) was resumed at JPMorgan as Overweight with a $79 price target. The stock traded near $64 on Thursday, in a 52-week range of $28.00 to $66.23. It has a consensus price target of $65.68.
CRISPR Therapeutics A.G. (NASDAQ: CRSP) was initiated with a Market Perform rating and a $160 price target at JMP Securities. The consensus price target is $157.40. Shares traded around $118 on Thursday, in a 52-week range of $32.30 to $220.20.
General Electric Co. (NYSE: GE) was reiterated with an Overweight rating and its price target was raised to $17 from $13 at Morgan Stanley. The stock traded near $13 on Thursday. The 52-week trading range is $5.48 to $14.13. Analysts have a consensus price target of $12.37.
Wheaton Precious Metals Corp. (NYSE: WPM) was initiated at JPMorgan with an Overweight rating with a $56 price target. The consensus price target is $60.43. Shares traded around $36 on Thursday, in the 52-week range of $18.66 to $57.89.
Yext Inc. (NYSE: YEXT) was downgraded by William Blair to Market Perform with an Outperform rating. Early Thursday, the stock traded near $14. The 52-week range is $8.56 to $20.90, and the consensus price target is $19.73.
[recirclink id=845156]
BofA Securities feels four top medtech companies are all poised for potential positive news and developments in the near future. Their stocks could be good additions to growth portfolios looking to add positions in the sector.
Does Target have 50% upside after earnings? Why did one analyst double its price target on Kohl’s?
Also, see why Deutsche Bank thinks Snowflake is due for a bounce, and Walmart is considering a SPAC IPO.
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
